Status:
COMPLETED
Effects of Metformin in a Non-Diabetic Patient Population
Lead Sponsor:
Brian Zuckerbraun
Conditions:
Inflammatory Response
Eligibility:
All Genders
55-85 years
Phase:
PHASE1
PHASE2
Brief Summary
Metformin has a well-established safety profile and it has become clear that metformin has additional salutary effects, including anti-inflammatory, anti-aging, and anti-thrombotic properties. In this...
Detailed Description
Metformin is considered first-line therapy for patients with type two diabetes with hyperglycemia that cannot be controlled with lifestyle alone. Unlike other oral medications, metformin is favored fo...
Eligibility Criteria
Inclusion
- Age ≥55 and ≤85 years of age
- Non-diabetic
- Adjusted risk analysis index (RAI) 20-42
- Estimated glomerular filtration rate \>45
- No evidence of hepatic dysfunction on comprehensive metabolic panel
- No clinical evidence of cardiac failure
- Existing University of Pittsburgh Medical Center Patients
Exclusion
- Hypersensitivity to metformin or any component of the formulation
- Acute or chronic metabolic acidosis with or without coma
- Pregnant or breastfeeding females
- Evidence or history of hepatic, renal, or cardiopulmonary failure
- Excessive acute or chronic ethanol use
- Planned or known hospital admission, exposure to anesthesia, or surgical intervention 30 days prior to study or scheduled 30 days after the trial initiation
- Laboratory analysis showing HbgA1c \>6.1 or eGFR \<44 on baseline labs
Key Trial Info
Start Date :
January 22 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2020
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT03772964
Start Date
January 22 2019
End Date
March 31 2020
Last Update
January 11 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15209